Clinical Trial Update: Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

This update reports a Phase 2 neoadjuvant study of carboplatin plus docetaxel in triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Mothaffar Rimawi | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-11-13